Prenatal Screening Tests
A quad screen flags risk, not diagnosis — yet students routinely treat abnormal results as confirmatory. Knowing what each screening actually tells you changes every next step.
Core Concept
Prenatal screening tests estimate the probability of chromosomal abnormalities and neural tube defects without confirming them. First-trimester screening (weeks 10–13) combines nuchal translucency ultrasound with maternal serum markers (free β-hCG and PAPP-A). Increased nuchal translucency with high β-hCG and low PAPP-A raises suspicion for trisomy 21. The quad screen (weeks 15–20) measures AFP, hCG, estriol, and inhibin A. Elevated AFP suggests an open neural tube defect; low AFP with high hCG and inhibin A suggests Down syndrome. Cell-free fetal DNA (cfDNA) testing can be drawn as early as 10 weeks and screens for trisomies 13, 18, and 21 with high sensitivity, but it remains a screening test — not diagnostic. An abnormal screen means the client needs counseling and a referral for diagnostic testing such as amniocentesis or CVS. The nurse's role centers on ensuring the client understands that a positive screen does not equal a diagnosis, managing anxiety, confirming accurate gestational dating (which directly affects AFP interpretation), and supporting informed decision-making without directing the outcome.
Watch Out For
Don't confuse screening (risk probability) with diagnostic tests like amniocentesis (definitive karyotype) — this atom covers screens only. Students mix up high AFP (neural tube defect) with low AFP (Down syndrome); the direction of AFP is the pivot point. cfDNA is highly accurate but is still classified as screening, not diagnosis.
Clinical Pearl
AFP goes UP for open defects (think: open tube leaks protein out) and DOWN for Down syndrome. Direction of AFP tells you the worry.
Test Your Knowledge
3 quick questions — see how well you understood Prenatal Screening Tests